AB5352
Anti-Amyloid Precursor Protein Antibody, CT
serum, Chemicon®
Sinonimo/i:
APP
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Codice UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Prodotti consigliati
Origine biologica
rabbit
Livello qualitativo
Forma dell’anticorpo
serum
Tipo di anticorpo
primary antibodies
Clone
polyclonal
Reattività contro le specie
human, monkey
Produttore/marchio commerciale
Chemicon®
tecniche
immunocytochemistry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
N° accesso NCBI
N° accesso UniProt
Condizioni di spedizione
dry ice
modifica post-traduzionali bersaglio
unmodified
Informazioni sul gene
human ... APP(351)
Specificità
Recognizes Amyloid Precursor Protein (APP), C-terminal. Recognizes full length APP and C-terminal fragments resulting from cleavage by secretase. May react with APLP1 and APLP2.
Immunogeno
Epitope: C-terminus
Nine amino acid peptide from the C-terminus of APP (YKFFEQMQN)
Applicazioni
Detect Amyloid Precursor Protein using this Anti-Amyloid Precursor Protein Antibody, C-terminus validated for use in IC, IH, IP & WB.
Immunohistochemistry: 1:100-1:400
Immunocytochemistry on NTera2 and COS cell lines: 1:100-1:400
Western blot: 1:500-1:2000: The low abundance of full length APP in untreated cells means that poor response is seen with immunoblotting of whole cell lysates. We recommend that membrane fractions be prepared to increase the loading of APP as well as remove potential interferences from soluable proteins. NTera2, Cos7 and Hela cell membrane preparations are positive by western blots.
Immunoprecipitation: 1:100-1:400.
Optimal working dilutions must be determined by end user.
Immunocytochemistry on NTera2 and COS cell lines: 1:100-1:400
Western blot: 1:500-1:2000: The low abundance of full length APP in untreated cells means that poor response is seen with immunoblotting of whole cell lysates. We recommend that membrane fractions be prepared to increase the loading of APP as well as remove potential interferences from soluable proteins. NTera2, Cos7 and Hela cell membrane preparations are positive by western blots.
Immunoprecipitation: 1:100-1:400.
Optimal working dilutions must be determined by end user.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
Stato fisico
Serum. Liquid in PBS with 0.02% azide.
Unpurified
Stoccaggio e stabilità
Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Risultati analitici
Control
Brain
Brain
Altre note
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Note legali
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Esclusione di responsabilità
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Motore di ricerca dei prodotti.
Raccomandato
N° Catalogo
Descrizione
Determinazione del prezzo
Codice della classe di stoccaggio
10 - Combustible liquids
Classe di pericolosità dell'acqua (WGK)
WGK 2
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
R van Dijk et al.
Journal of neurochemistry, 90(3), 712-723 (2004-07-17)
Frame-shifted amyloid precursor protein (APP(+1)), which has a truncated out-of-frame C-terminus, accumulates in the neuropathological hallmarks of patients with Alzheimer's disease pathology. To study a possible involvement of APP(+1) in the pathogenesis of Alzheimer's disease, we expressed APP695 and APP(+1)
GGA proteins mediate the recycling pathway of memapsin 2 (BACE).
He, X; Li, F; Chang, WP; Tang, J
The Journal of Biological Chemistry null
Cara L Croft et al.
Cell death & disease, 8(3), e2671-e2671 (2017-03-17)
The spatiotemporal transmission of pathological tau in the brain is characteristic of Alzheimer's disease. Release of both soluble and abnormal tau species from healthy neurons is increased upon stimulation of neuronal activity. It is not yet understood whether the mechanisms
Virgil Muresan et al.
Neuro-degenerative diseases, 13(2-3), 122-125 (2013-09-07)
The pathology of amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder affecting motor neurons, comprises aberrant accumulations of neurofilaments; mutations in the peripherin subunit of neurofilaments have been identified in some forms of ALS. Recently, the amyloid-β precursor protein (APP), a
A Kamal et al.
Neuron, 28(2), 449-459 (2001-01-06)
We analyzed the mechanism of axonal transport of the amyloid precursor protein (APP), which plays a major role in the development of Alzheimer's disease. Coimmunoprecipitation, sucrose gradient, and direct in vitro binding demonstrated that APP forms a complex with the
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.